Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ayala Pharmaceuticals, Inc. (AYLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.50-0.34 (-4.97%)
At close: 04:00PM EST
6.50 -0.09 (-1.37%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.84
Open6.97
Bid6.10 x 800
Ask7.50 x 900
Day's Range6.41 - 7.31
52 Week Range6.26 - 28.68
Volume57,295
Avg. Volume29,912
Market Cap90.579M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.87
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.38
  • TipRanks

    Buy These 2 Small-Cap Stocks to Double Your Investment, Say Analysts

    Let’s not beat about the bush too much. At the end of the day every investor wants to see a strong return on their outlay. The stronger, the better. The thing is, the markets are predicated on a simple equation. Go with the safer bets, i.e. the mega-caps, and you will probably make bank, although less likely to see enormous gains. On the other hand, take a chance on a smaller, less established name and the rewards could be far grander. However, there’s a catch; this is a risky play and you are f

  • GlobeNewswire

    Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

    REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022. A webcast of the presentation will be ava

  • GlobeNewswire

    Ayala Pharmaceuticals Announces Key Business Objectives for 2022

    -- Data read-outs expected on AL102 in desmoid tumors and AL101 in ACC and TNBC --REHOVOT, Israel and WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced its key objectives for 2022. “We believe that 2022 will be a pivotal ye

Advertisement
Advertisement